CF PharmTech closes RMB360m Series F round

On July 2, CF PharmTech, following its completion of 630 million yuan Series E round in January, completed a Series F round of financing, raising 360 million yuan.

On July 2, CF PharmTech, following its completion of 630 million yuan Series E round in January, completed a Series F round of financing, raising 360 million yuan. In total, the company raised nearly one billion yuan in financing in six months.

The latest financing round was jointly led by BioTrack Capital and CICC Qichen, with participation from renowned institutions such as CICC Qide, SAIC Hengxu, GP M&A Fund and Watson Investment. In the meantime, its existing investors including Passion Capital and Yuanming Capital also participated.

CEC Capital served as CF PharmTech’s sole financial advisor for both Series E round and Series F round.

CF PharmTech is a fully integrated specialty pharmaceutical company dedicated to providing affordable and high-quality respiratory drugs globally.Managed by a high caliber team with extensive experience in the industry, the company focuses on the development of drugs for the treatment of respiratory diseases.

http://www.cfpharmtech.com/html/en/mediacenter/industrynews/183.html

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/03/cf-pharmtech-closes-rmb360m-series-f-round/.

Leave a Reply

Please Login to Comment